American global pharmaceutical company Eli Lilly on Friday cleared the first trial involving claims that its antidepressant Cymbalta caused severe withdrawal symptoms, including suicidal thoughts and electric shock-like sensations.
It has been said that the Indianapolis based pharmaceutical company was sued roughly by 250 plaintiffs who claimed that the company downplayed warnings about symptoms that occur after a patient quits the drug.
The trial about Cymbalta, which has annual sales of about $3.9 billion, is the first of four trials scheduled for this month.The lawsuit was filed by Claudia Herrera in federal court in California,
The American global pharmaceutical company Eli Lilly is releasing results from a clinical trial of solanezumab. Solanezumab binds the amyloid-? peptides that aggregate and form plaques in the brain that are an early pathological feature of Alzheimer's disease.
The researchers associated with the trial stated that for the trial they focused on two major approaches i.e. involving getting rid of the plaques, and developing drugs that counter the memory loss caused by the Alzheimer’s disease.
Researchers noted that if it is given in the early stage of the disease it slowed down the rate of deterioration of the brain cells resulting in more time for the patients to remain lucid.
Results of the new Phase 3 study, called REACH-2, conducted by Eli Lilly and Co., showed that Cyramza therapy did not significantly improve overall survival in patients with advanced hepatocellular carcinoma (HCC) also known as liver cancer.
The liver cancer trial was conducted to see if Cyramza is effective in fighting one of the deadliest cancers. On Friday, Lilly said that Cyramza didn't help patients live significantly longer than patients who were getting a placebo and best supportive care.
Although the selected HCC patients with elevated baseline alpha-fetoprotein (AFP), a liver enzyme, did show improvement in survival after receiving ramucirumab, it was not statistically significant.
On Monday, shares of Eli Lilly increased 1.32% to $77.12 in afternoon trading. The shares rose after announcement made by the company that it would carry out late-stage studies with Pfizer (PFE) for their drug, tanezumab. The decision was taken by the company after the Food and Drug Administration decided to lift the partial hold on the trials of these kinds of drugs.
The FDA stopped testing of the chronic pain treatment and also on the ones, which work by blocking a protein called nerve growth factor on account of nervous system complications. Researchers observed these issues while testing the drugs on animals.
Eli Lilly & Co has agreed to pay a sum of $29.4 million in fines to settle the allegations made by the U. S. Securities and Exchange Commission into the cases of bribe given by the employees of its units in different countries.
The US Securities and Exchange Commission has alleged that staff members of its subsidiaries gave cash and gifts to officials in China, Brazil, Russia and Poland in order to secure business deals in those countries worth millions of dollars.
Bangalore-based Strides Arcolab Ltd has join forces with US-based pharmaceuticals firm Eli Lilly & Co to expand the marketing of generic oral as well as injectable cancer medicines in emerging markets.
As a part of the partnership deal, Eli Lilly will in-license a portfolio of branded generic cancer treatment drugs manufactured by Agila Specialties - the specialties arm of Strides Arcolab Ltd.
Bangalore-based Strides Arcolab has said that it is entering into a partnership with global pharmaceutical major Eli Lilly and Co for expanding delivery of cancer medicines in emerging countries.
Under the agreement, Lilly will in-license a portfolio of branded generic injectable and oral cancer medicines from Agila Specialties, which is a unit of Strides Arcolab. Agila Specialties will be responsible for manufacturing cancer medicines and Lilly will register and market the drugs in several countries across the world.
Acrux Ltd. and US-based Eli Lilly and Company have signed a license agreement. As per these Acrux will be make a testosterone solution and Eli Lily would be commercializing it. The name of the solution is Axiron.
The medicine will be used in treating men who suffer from low level of testosterone.
Under the license, Eli Lily will have the exclusive rights to sell the drug worldwide. And Acrux will receive an upfront payment of $50 million and another $3 million for transfer of manufacturing equipments.
- Marathon Pharma to sell decades-old drug to treat DMD for $89,000
- FedEx Launches FedEx Fulfillment for Small Business to Compete with Amazon
- CDC updates 2017 advisory for recommended flu shots
- Coca-Cola Helped by Strong North American Demand but Company Issues Lackluster Future Guidance
- Women with dense breasts more likely to develop breast cancer: study